Generic Vyvanse became available starting in August 2023, following the expiration of the U.S. patent for Vyvanse. Multiple generic manufacturers were approved by the FDA, and generic versions have been shipping since then. However, there have been ongoing supply shortages and some regulatory and manufacturing challenges affecting availability, with some specific dosages like 40 mg currently on back order with expected restock dates in late October 2025.
Summary of Generic Vyvanse Availability
- Generic Vyvanse approved and started shipping from August 2023.
- Multiple manufacturers (at least 14) have FDA approval to produce it.
- Some shortages and backorders exist, notably 40 mg capsules expected available by late October 2025.
- Production increases have been approved by DEA to address supply issues.
- Patients should check pharmacy availability and insurance coverage, as some generics may require prior authorization.
This means generic Vyvanse is already on the market but availability may be limited depending on dosage and supply chain factors.
